查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1766138

爱德华兹症候群治疗市场预测（至 2032 年）：按治疗类型、类型、最终用户和地区进行的全球分析

Edward's Syndrome Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type (Supportive Care/Palliative Care, Potential Future Therapies and Other Treatment Types), Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球爱德华兹症候群治疗市场预计在 2025 年将达到 56 亿美元，到 2032 年将达到 89 亿美元，预测期内的复合年增长率为 6.9%。爱德华兹症候群（18 三体）没有明确的治疗方法，治疗以支持治疗和安宁疗护为主。医疗介入旨在控制危及生命的併发症，例如心臟缺陷、饮食障碍和呼吸问题。新生儿可能需要新生儿加护治疗，长期倖存者可受益于多学科支援以改善他们的生活品质。这通常取决于症状的严重和家庭的意愿。此方法强调舒适度、道德考量和个人化的护理计划。

根据《儿科学杂誌》 2022 年的一篇评论，大约 50% 的爱德华兹氏症婴儿能够活过出生后的第一周，但即使经过精心医疗护理，也只有不到 10% 的婴儿能够活过 1 岁。

更重视安宁疗护与舒适护理

爱德华兹氏症候群的治疗格局已发生显着变化，人们更加重视改善这种危及生命的疾病患者的生活品质。由于目前尚无确定性的治疗方法，医疗重点已转向透过症状管理和安宁疗护来提高患者的舒适度。医疗保健提供者优先考虑支持性护理策略，以最大限度地减轻患者的痛苦并改善其功能健康，尤其是在新生儿和婴儿早期。

死亡率高，预期寿命短

大多数患者活不过出生后一年，影响了综合治疗性介入介入的发展空间。如此短的预期寿命往往导致医疗方法更为保守，而较少重视积极治疗。此外，侵入性手术决策过程中的情绪和伦理挑战进一步限制了治疗的普及。

投资罕见疾病研究和孤儿药认定

罕见疾病治疗计画等策略性资金鼓励製药公司研究标靶治疗，以服务这些医疗资源匮乏的病患群体。政府和监管机构提供快速核准途径和财政奖励，以鼓励产前检测和基因调控疗法的创新。学术机构也与生技公司合作，利用分子研究探索新的治疗方法。

错误讯息和不一致讯息

关于治疗方案（尤其是维持生命的干预措施）的意见分歧，导致看护者和医疗保健专业人员感到困惑。缺乏集中的实证照护资讯来源，阻碍了就最佳实践达成共识，尤其是在资源匮乏的地区。此外，不同文化和卫生系统对先天性疾病管理的态度差异加剧了不确定性。

COVID-19的影响

COVID-19危机为爱德华兹症候群等罕见复杂疾病患者带来了更多挑战。新生儿加护病房(NICU) 和小儿科的诊疗服务中断，导致重症加护期间的及时干预措施被延误。封锁措施和医疗系统的压力导致诊断筛检被推迟。然而，疫情促使远端医疗和虚拟咨商的广泛应用，为家庭提供持续的心理社会支持和决策指导。

预测期内，支持性/安宁疗护领域预计将实现最大幅度成长

由于缺乏改善病情的治疗方法，预计支持性/安宁疗护领域将在预测期内占据最大的市场占有率。这些护理方法着重于透过解决饮食障碍、呼吸系统疾病和疼痛管理来减轻患者及其家属的身心负担。医院越来越多地整合由新生儿科医生、护士、咨商师和社会工作者组成的多学科安宁疗护团队，以改善以病人为中心的治疗效果。

预计在预测期内，镶嵌型 18 三体症片段的复合年增长率最高。

18三体嵌合型病例预计将在预测期内实现最高成长率，这得益于其相对良好的预后和延长存活期的潜力。此类患者通常症状较轻，更有可能从个人化治疗策略中获益。基因筛检和核型分析技术的进步使得嵌合型的早期发现成为可能，鼓励临床医生探索标靶治疗的途径。

比最大的地区

由于产前筛检基础设施的改善和新生儿保健设施的普及，预计亚太地区将在预测期内占据最大的市场占有率。在中国、印度和日本等国家，国家健康宣传活动和早期疗育计画提高了人们对染色体异常的认识。母胎医学的投资以及非侵入性产前检测 (NIPT) 的进步显着扩展了诊断范围。

复合年增长率最高的地区

在预测期内，北美地区预计将呈现最高的复合年增长率，这得益于其强大的罕见疾病政策框架和先进的医疗基础设施。津贴和税额扣抵等针对罕见疾病的专门融资管道的存在，加速了该领域的研发。美国和加拿大已建立专门治疗遗传疾病的临床护理中心网络，为复杂的新生儿病例提供多学科管理。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 透过产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 二手研究资料
    • 先决条件

第三章市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球爱德华兹氏症候群治疗市场（依治疗类型）

  • 介绍
  • 支持性/安宁疗护
    • 心臟治疗
    • 辅助餵食
    • 整形外科治疗
    • 心理社会支持
    • 早期疗育计划
    • 筛检和监测
  • 未来潜在的治疗方法
    • 基因治疗
    • 个人化医疗
  • 其他类型的治疗

6. 全球爱德华兹氏症候群治疗市场（按类型）

  • 介绍
  • 完全性18三体综合症
  • 18三体嵌合体
  • 18部分三体综合征

7. 全球爱德华兹氏症候群治疗市场（依最终用户）

  • 介绍
  • 医院
  • 诊所
  • 门诊手术中心
  • 其他的

8. 全球爱德华兹氏症候群治疗市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第九章 主要进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司概况

  • Thermo Fisher Scientific Inc.
  • Stryker Corporation
  • Quest Diagnostics
  • PerkinElmer Inc.
  • Natera, Inc.
  • Myriad Genetics, Inc.
  • Masimo Corporation
  • Koninklijke Philips NV
  • Invitae Corporation
  • Illumina, Inc.
  • GE HealthCare
  • F. Hoffmann-La Roche Ltd.
  • Eurofins Scientific
  • Centogene NV
  • Boston Scientific Corporation
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Abbott Laboratories
Product Code: SMRC29994

According to Stratistics MRC, the Global Edward's Syndrome Treatment Market is accounted for $5.6 billion in 2025 and is expected to reach $8.9 billion by 2032 growing at a CAGR of 6.9% during the forecast period. Edward's Syndrome, or Trisomy 18, has no definitive cure; treatment focuses on supportive and palliative care. Medical interventions aim to manage life-threatening complications such as heart defects, feeding difficulties, and respiratory issues. Newborns may require neonatal intensive care, while long-term survivors benefit from multidisciplinary support to improve quality of life. Decisions are often guided by the severity of symptoms and family preferences. The approach emphasizes comfort, ethical considerations, and individualized care planning.

According to a 2022 review in The Journal of Pediatrics, about 50% of infants with Edward's Syndrome survive beyond the first week of life, but less than 10% live past their first year, even with intensive medical care.

Market Dynamics:

Driver:

Growing focus on palliative and comfort care

The increasing emphasis on improving the quality of life for patients with life-limiting conditions is significantly shaping the Edwards Syndrome treatment landscape. With no definitive cure currently available, the medical focus is shifting toward enhancing patient comfort through symptom management and palliative interventions. Healthcare providers are prioritizing supportive care strategies to minimize suffering and improve functional well-being, especially during neonatal and early infancy stages.

Restraint:

High mortality rate and short life expectancy

The majority of patients do not live beyond the first year of life, which impacts the scope for developing comprehensive therapeutic interventions. This short life expectancy often leads to a more conservative medical approach, with limited emphasis on aggressive treatment. Additionally, the emotional and ethical challenges surrounding decision-making for invasive procedures further limit treatment adoption.

Opportunity:

Investment in rare disease research and orphan drug designations

Strategic funding initiatives, such as orphan drug programs, are encouraging pharmaceutical companies to explore targeted therapies that cater to these underserved patient groups. Governments and regulatory authorities are offering accelerated approval pathways and financial incentives, fostering innovation in prenatal diagnostics and gene-modulating treatments. Academic institutions are also collaborating with biotech firms to explore new therapeutic angles using molecular research.

Threat:

Misinformation and lack of consistent information

Conflicting opinions on treatment protocols-particularly regarding life-sustaining interventions can lead to confusion among caregivers and healthcare professionals. Lack of centralized resources for evidence-based care impedes consensus on best practices, especially in resource-limited regions. Additionally, varying attitudes across cultures and medical systems toward managing congenital disorders exacerbate uncertainty.

Covid-19 Impact:

The COVID-19 crisis created additional difficulties for patients with rare and complex conditions like Edwards Syndrome. Disrupted access to neonatal intensive care units (NICUs) and pediatric specialists delayed timely interventions during critical care windows. Lockdowns and strained healthcare systems resulted in postponed diagnostic screenings. However, the pandemic also prompted broader adoption of telemedicine and virtual counseling, which provided families with continuity in psychosocial support and decision-making guidance.

The supportive care/palliative care segment is expected to be the largest during the forecast period

The supportive care/palliative care segment is expected to account for the largest market share during the forecast period given the absence of disease-altering therapies. These care approaches focus on easing the physical and emotional burden on patients and their families by managing feeding difficulties, respiratory issues, and pain. Hospitals are increasingly integrating interdisciplinary palliative care teams comprising neonatologists, nurses, counselors, and social workers to improve patient-centered outcomes.

The mosaic trisomy 18 segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mosaic trisomy 18 segment is predicted to witness the highest growth rate due to comparatively better prognostic outcomes and extended survival potential. Patients with this form often exhibit milder symptoms and may benefit more from individualized treatment strategies. Advances in genetic screening and karyotyping have enhanced early detection of mosaicism, prompting clinicians to explore targeted therapeutic paths.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share owing to improved prenatal screening infrastructure, and expanding access to neonatal care facilities. Nations such as China, India, and Japan are witnessing rising awareness of chromosomal anomalies due to national health campaigns and early intervention programs. Investments in maternal-fetal medicine and advances in non-invasive prenatal testing (NIPT) have significantly enhanced diagnostic coverage.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by robust rare disease policy frameworks and advanced healthcare infrastructure. The presence of dedicated funding channels for orphan diseases, including grants and tax credits, is accelerating research and development in this domain. The U.S. and Canada have established networks of clinical care centers that specialize in genetic disorders, offering multidisciplinary management for complex neonatal cases.

Key players in the market

Some of the key players in Edward's Syndrome Treatment Market include Thermo Fisher Scientific Inc., Stryker Corporation, Quest Diagnostics, PerkinElmer Inc., Natera, Inc., Myriad Genetics, Inc., Masimo Corporation, Koninklijke Philips N.V., Invitae Corporation, Illumina, Inc., GE HealthCare, F. Hoffmann-La Roche Ltd., Eurofins Scientific, Centogene N.V., Boston Scientific Corporation, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc and Abbott Laboratories.

Key Developments:

In June 2025, Thermo Fisher introduced the Orbitrap Astral Zoom and Orbitrap Excedion Pro mass spectrometers at the ASMS 2025 conference, offering exceptional speed, sensitivity and resolution for biopharma and omics research.

In February 2025, Thermo Fisher entered a definitive agreement to buy Solventum's Purification & Filtration division for approximately $4.1 billion, expanding its bioprocessing and biologics manufacturing capabilities.

In January 2025, Stryker agreed to acquire Inari Medical in an all-cash deal, strengthening its peripheral vascular disease treatment portfolio and enhancing endovascular procedural offerings.

Treatment Types Covered:

  • Supportive Care/Palliative Care
  • Potential Future Therapies
  • Other Treatment Types

Types Covered:

  • Full Trisomy 18
  • Mosaic Trisomy 18
  • Partial Trisomy 18

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Edward's Syndrome Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Supportive Care/Palliative Care
    • 5.2.1 Cardiac Treatment
    • 5.2.2 Assisted Feeding
    • 5.2.3 Orthopedic Treatment
    • 5.2.4 Psychosocial Support
    • 5.2.5 Early Intervention Programs
    • 5.2.6 Screening & Monitoring
  • 5.3 Potential Future Therapies
    • 5.3.1 Gene Therapy
    • 5.3.2 Personalized Medicine
  • 5.4 Other Treatment Types

6 Global Edward's Syndrome Treatment Market, By Type

  • 6.1 Introduction
  • 6.2 Full Trisomy 18
  • 6.3 Mosaic Trisomy 18
  • 6.4 Partial Trisomy 18

7 Global Edward's Syndrome Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Clinics
  • 7.4 Ambulatory Surgical Centres
  • 7.5 Other End Users

8 Global Edward's Syndrome Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Thermo Fisher Scientific Inc.
  • 10.2 Stryker Corporation
  • 10.3 Quest Diagnostics
  • 10.4 PerkinElmer Inc.
  • 10.5 Natera, Inc.
  • 10.6 Myriad Genetics, Inc.
  • 10.7 Masimo Corporation
  • 10.8 Koninklijke Philips N.V.
  • 10.9 Invitae Corporation
  • 10.10 Illumina, Inc.
  • 10.11 GE HealthCare
  • 10.12 F. Hoffmann-La Roche Ltd.
  • 10.13 Eurofins Scientific
  • 10.14 Centogene N.V.
  • 10.15 Boston Scientific Corporation
  • 10.16 Bio-Rad Laboratories, Inc.
  • 10.17 Agilent Technologies, Inc.
  • 10.18 Abbott Laboratories

List of Tables

  • Table 1 Global Edward's Syndrome Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Edward's Syndrome Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Edward's Syndrome Treatment Market Outlook, By Supportive Care/Palliative Care (2024-2032) ($MN)
  • Table 4 Global Edward's Syndrome Treatment Market Outlook, By Cardiac Treatment (2024-2032) ($MN)
  • Table 5 Global Edward's Syndrome Treatment Market Outlook, By Assisted Feeding (2024-2032) ($MN)
  • Table 6 Global Edward's Syndrome Treatment Market Outlook, By Orthopedic Treatment (2024-2032) ($MN)
  • Table 7 Global Edward's Syndrome Treatment Market Outlook, By Psychosocial Support (2024-2032) ($MN)
  • Table 8 Global Edward's Syndrome Treatment Market Outlook, By Early Intervention Programs (2024-2032) ($MN)
  • Table 9 Global Edward's Syndrome Treatment Market Outlook, By Screening & Monitoring (2024-2032) ($MN)
  • Table 10 Global Edward's Syndrome Treatment Market Outlook, By Potential Future Therapies (2024-2032) ($MN)
  • Table 11 Global Edward's Syndrome Treatment Market Outlook, By Gene Therapy (2024-2032) ($MN)
  • Table 12 Global Edward's Syndrome Treatment Market Outlook, By Personalized Medicine (2024-2032) ($MN)
  • Table 13 Global Edward's Syndrome Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 14 Global Edward's Syndrome Treatment Market Outlook, By Type (2024-2032) ($MN)
  • Table 15 Global Edward's Syndrome Treatment Market Outlook, By Full Trisomy 18 (2024-2032) ($MN)
  • Table 16 Global Edward's Syndrome Treatment Market Outlook, By Mosaic Trisomy 18 (2024-2032) ($MN)
  • Table 17 Global Edward's Syndrome Treatment Market Outlook, By Partial Trisomy 18 (2024-2032) ($MN)
  • Table 18 Global Edward's Syndrome Treatment Market Outlook, By End User (2024-2032) ($MN)
  • Table 19 Global Edward's Syndrome Treatment Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 20 Global Edward's Syndrome Treatment Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 21 Global Edward's Syndrome Treatment Market Outlook, By Ambulatory Surgical Centres (2024-2032) ($MN)
  • Table 22 Global Edward's Syndrome Treatment Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.